Predictors of Change in % Predicted FVC over Time in Scleroderma (SSc) Interstitial Lung Disease (ILD): Findings from the Scleroderma Lung Study (SLS).

被引：0
|
作者：
Tashkin, D. P. [1 ]
Elashoff, D. [1 ]
Roth, M. D. [1 ]
Furst, D. E. [1 ]
Khanna, D. [1 ]
Clements, P. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2009年 / 179卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3940
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Silver, R.
    RHEUMATOLOGY, 2012, 51 : I12 - I12
  • [2] Correlation of Cough With Disease Activity and Treatment With Cyclophosphamide in Scleroderma Interstitial Lung Disease Findings From the Scleroderma Lung Study
    Theodore, Arthur C.
    Tseng, Chi-Hong
    Li, Ning
    Elashoff, Robert M.
    Tashkin, Donald P.
    CHEST, 2012, 142 (03) : 614 - 621
  • [3] Telomere (TL) shortening is associated with disease severity in scleroderma (SSC) associated interstitial lung disease (ILD)
    Adamali, Huzaifa I.
    Delgado, Cesar M.
    Stock, Carmel
    Lindhal, Gisela E.
    Molyneaux, Phil
    Russell, Anne-Marie
    Wells, Athol
    Renzoni, Elizabeth A.
    Maher, Toby
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [4] Predicting the course of %FVC: Lessons learned in the Scleroderma Lung Study (SLS)
    Clements, P.
    Furst, D. E.
    Khanna, D.
    Elashoff, R.
    Li, Ning
    Roth, M.
    Tashkin, D.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S824 - S825
  • [5] TYPE 2 (TH2) CYTOKINES AND SCLERODERMA INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Pellicano, C.
    Vantaggio, L.
    Colalillo, A.
    Pocino, K.
    Basile, V.
    Marino, M.
    Basile, U.
    Rosato, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 977 - 978
  • [6] MYCOPHENOLATE MOFETIL (MMF) IN SCLERODERMA (SSc) ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD) AND SKIN DISEASE - THE AUSTRALIAN EXPERIENCE
    Jayaweera, S.
    Sahhar, J.
    Englert, H.
    Proudman, S.
    Hill, C.
    Youssef, P.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 11 - 11
  • [7] Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II
    Tashkin, Donald
    Roth, Michael
    Clements, Philip
    Furst, Daniel
    Khanna, Dinesh
    Goldin, Jonathan
    Kleerup, Eric
    Arriola, Edgar
    Tseng, Chi-Hong
    Elashoff, Robert
    CHEST, 2015, 148 (04)
  • [8] A COMPARISON OF FVC, FVC/DLCO AND TLC/DLCO AS AN INDICATOR FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SCLERODERMA
    Halasan, Carol
    Korzan, Sophie
    Datta, Debapriya
    CHEST, 2018, 154 (04) : 448A - 448A
  • [9] The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
    Clements, Philip J.
    Tashkin, Donald
    Roth, Michael
    Khanna, Dinesh
    Furst, Daniel E.
    Tseng, Chi-hong
    Volkmann, Elizabeth R.
    Elashoff, Robert
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [10] Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease
    Parmar, Manpreet
    Carnaru, Miruna
    Patel, Anand
    Hsu, Vivien
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345